Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development  in vitro  and  in vivo

Jian Lu; Min Chen; Zhenhua Tao; Sumeng Gao; Yang Li; Yu Cao; Chun Lu; Xiaoping Zou

doi:10.18632/oncotarget.19479

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo

Jian Lu, Min Chen, Zhenhua Tao, Sumeng Gao, Yang Li, Yu Cao, Chun Lu _ and Xiaoping Zou

PDF | HTML | How to cite

Oncotarget. 2017; 8:76458-76467. https://doi.org/10.18632/oncotarget.19479

Metrics: PDF 1810 views | HTML 2649 views | ?

Abstract

Jian Lu1,2,3,*, Min Chen1,3,*, Zhenhua Tao2, Sumeng Gao3, Yang Li1, Yu Cao1, Chun Lu4 and Xiaoping Zou1,3

1Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, P.R. China

2Department of Gastroenterology, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi 214002, P.R. China

3Department of Gastroenterology, The Affiliated Drum Tower Hospital of Nanjing University, Medical School, Nanjing 210008, P.R. China

4Department of Microbiology, Nanjing Medical University, Nanjing 211116, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Chun Lu, email: [email protected]

Xiaoping Zou, email: [email protected]

Keywords: SLC1A5, gastric cancer, cell proliferation, cell motility

Received: April 15, 2017 Accepted: June 10, 2017 Published: July 22, 2017

ABSTRACT

Aims: To investigate the oncogenic effects of SLC1A5 on gastric cancer development in vitro and in vivo.

Methods: The expression level of SLC1A5 was detected in 70 gastric cancer paraffin-embedded tissues by immunohistochemistry and also was detected in gastric cancer cell lines by qRT-PCR and western blotting analysis. The effects of knockdown SLC1A5 were analyzed on cell proliferation, cell cycle, the ability of cell migration and invasion and growth signaling pathway in vitro. By using subcutaneous xenograft mouse, the importance of SLC1A5 expression was assessed for both successful engraftment and growth of gastric cancer cells in vivo.

Results: SLC1A5 was up-regulated in gastric cancer tissues and was correlated with malignant features such as deeper local invasion, higher lymph node metastasis, advanced TNM stages and higher Ki-67 expression. Knockdown SLC1A5 in gastric cancer cells suppressed cell proliferation, caused G0/G1 arrest and inhibited cell invasion as well as migration partly by inactivated mTOR/p-70S6K1 signaling pathway in vitro. Furthermore, in vivo experiments indicated that suppression of SLC1A5 could inhibit relative volume of xenografted tumor.

Conclusions: Our results suggested that SLC1A5 might be considered as a new biomarker and also as a potential therapeutic target in gastric cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19479

Publication Alerts

Research Papers:

Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo

Abstract